1 tablet contains 80 mg of drotaverine hydrochloride (Drotaverini hydrochloridum). Excipient with known effect: lactose monohydrate 182.5 mg.
Spastyna Max has as many as 20 indications for use:
1. Smooth muscle spasms associated with bile duct diseases: biliary stones,
cholecystitis, inflammation around the gallbladder, cholangitis, papillitis;
2. Smooth muscle spasms of urinary tract: kidney stones, ureteral stones, pyelonephritis, cystitis, painful urinary urgency.
As an adjunct treatment, the product can be used safely and with the desired effect:
1. In spasms of the smooth muscles of the gastrointestinal tract: gastric and duodenal ulcers, gastritis, enteritis, colitis, cardia and pyloric spasms, irritable bowel syndrome, spastic constipation and flatulence, pancreatitis;
2. In gynaecological conditions: dysmenorrhea
Hypersensitivity to drotaverine or any of the excipients; Severe hepatic impairment, severe renal impairment, circulatory failure; 2nd or 3rd degree AV block; Do not use in children under 12 years of age.
This is a drug. For safety, use it according to the package insert and only when necessary. If in doubt, consult your doctor or pharmacist.
This is a drug. For safety, use it according to the package insert and only when necessary. If in doubt, consult your doctor or pharmacist.
phone: (+48 22) 742 00 22
informacjaoleku@hasco-lek.pl
1 tablet contains 80 mg of drotaverine hydrochloride (Drotaverini hydrochloridum). Excipient with known effect: lactose monohydrate 182.5 mg.
Spastyna Max has as many as 20 indications for use:
1. Smooth muscle spasms associated with bile duct diseases: biliary stones,
cholecystitis, inflammation around the gallbladder, cholangitis, papillitis;
2. Smooth muscle spasms of urinary tract: kidney stones, ureteral stones, pyelonephritis, cystitis, painful urinary urgency.
As an adjunct treatment, the product can be used safely and with the desired effect:
1. In spasms of the smooth muscles of the gastrointestinal tract: gastric and duodenal ulcers, gastritis, enteritis, colitis, cardia and pyloric spasms, irritable bowel syndrome, spastic constipation and flatulence, pancreatitis;
2. In gynaecological conditions: dysmenorrhea
Hypersensitivity to drotaverine or any of the excipients; Severe hepatic impairment, severe renal impairment, circulatory failure; 2nd or 3rd degree AV block; Do not use in children under 12 years of age.
Przedsiębiorstwo Produkcji
Farmaceutycznej
Hasco-Lek S.A.
st. Żmigrodzka 242e
51-131 Wroclaw
phone: (+48) 71 352 95 22
fax: (+48) 71 352 76 36
hasco@hasco-lek.pl
